A recent study has calculated the average cost for drug development (including marketing approval) at $2.558 billion. According to Tufts Center for the Study of Drug Development, this figure was reached through estimating average out-of-pocket costs to be $1.395 billion and time costs to be $1.163 billion. Once the drug is approved, R&D costs for […]
A majority of large publicly held instrument and lab product companies ended 2015 on a strong note, benefiting from sustained demand from biopharmaceutical customers and steady growth in applied markets. Nevertheless, currency effects along with weak industrial markets continued to dampen organic top line growth. Moreover, several companies were negatively impacted by fewer selling days […]
There is likely to be an increase in spending by the pharmaceutical industry for 2016 due to an upsurge in demand. The long-term outlook for pharma is mostly positive, with projected average growth of 4.3% between 2015 and 2019, totaling $1.4 trillion in global pharma sales by 2019. The US, Brazil, Russia and China collectively […]
According to the Biotechnology Industry Organization (BIO), the EPA’s final rule for the 2014–2016 Renewable Fuel Standards (RFS) is “unnecessary and unlawful.” BIO stated that the EPA’s two-year delay in implementing the rule will continue to damage investment in advanced and cellulosic biofuels, and will increase greenhouse gas emissions in transportation-fuel sectors. The RFS ensure […]
A survey of 52 pharmaceutical industry and academic personnel involved in natural products (NP) drug discovery found a gap between NP drug discovery strategies and NP drug potential. Thirty-five respondents chose high-throughput screening (HTS) as the “top preferred current strategy.” However, it is not best suited for NP drug discovery, according to many respondents. For […]
Princeton, NJ 12/1/15—Certara has purchased XenologiQ, a quantitative systems pharmacology (QSP) consultancy for an undisclosed amount. According to Certara, “QSP is an emerging biosimulation discipline that combines computational modeling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process.” XenologiQ will become part of Certara’s Simcyp division, […]
According to a new report by Deloitte, R&D return on investments generated from the pharmaceutical industry’s annual investment in new product innovation have continued to decline. The annual projected R&D returns were 10.1% in 2010; in 2015, the returns were down to 4.2%. Since 2010, Deloitte’s original cohort of 12 companies has launched 186 products […]
Agilent Maintains Cautious Outlook Agilent Technologies’ fiscal fourth quarter revenues ending October 31 fell 0.8% to $1.04 billion, in line with expectations. Excluding currency and divestments, which reduced revenue growth by 6.4% and 0.6%, respectively, organic sales rose 6.2%. All sales figures are organic. Sales to analytical lab markets grew roughly 6% to account for […]
By 2020, spending on medicines will total $1.4 trillion, a 29%–32% increase in constant dollars from 2015, but down from 35% growth over the previous five-year period. The volume of medicines used from 2015 to 2020 will increase 24%. Original brands, nonoriginal brands, unbranded and OTC medicines will account for 52%, 21%, 14% and 13% […]
In 2015, 94% of the one thousand public firms globally that spend the most on R&D invested in R&D activities abroad. Their spending on these programs totaled $680 billion, up 5.1%, but revenues fell 1% due to the drop in oil prices. R&D intensity grew 0.2 percentage points to 3.7%. Asia is now the top […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
